CYSTADROPS: payments to doctors
Payments that named CYSTADROPS as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Recordati_rare_diseases_inc.?
Recordati_rare_diseases_inc. reported the most payments naming CYSTADROPS. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $37K
- Providers
- 262
- Transactions
- 332
- Average per transaction
- $113
The per-transaction average — $113 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 262 providers the average total is $143, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Recordati_rare_diseases_inc. | $37,353 | 100.0% |
Other products from Recordati_rare_diseases_inc.
The company that reported the most payments naming CYSTADROPS also reports against these.
- ISTURISA$1,070,940
- Sylvant$494,365
- PANHEMATIN$235,345
- SIGNIFOR LAR$186,015
- ENJAYMO$176,698
- OSILODROSTAT$158,129
- Carbaglu$84,613
- SILTUXIMAB$7,632
- CYSTADANE$3,598